Evidence map›Paper›PMID 15531767›Full record

Trial reportThe New England journal of medicine2004

Angiotensin-converting-enzyme inhibition in stable coronary artery disease.

Eugene Braunwald, Michael J Domanski, Sarah E Fowler, Nancy L Geller, Bernard J Gersh, Judith Hsia, Marc A Pfeffer, Madeline M Rice, Yves D Rosenberg, Jean L Rouleau and 1 more

3 registry-linked trialsOpen access · bronzeAbstract readClinical TrialMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The New England journal of medicine, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 260 papers, 30 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
260citing papers in PubMed, 30 pooled it
65.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00000558 phase3completednot on this map

Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy (PEACE)

TypeinterventionalSponsorNational Heart, Lung, and Blood Institute (NHLBI)Ran1995 to 2005ConditionsCardiovascular Diseases, Coronary Disease, Heart Diseases, Myocardial InfarctionArmsangiotensin-converting enzyme inhibitors
NCT00879060 phase4completednot on this mapstarted 2007, after this paper: background citation

Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy

TypeinterventionalSponsorTufts Medical CenterRan2007 to 2012Enrolled53ConditionsMyocardial Fibrosis, Hypertrophic CardiomyopathyArmsSpironolactone, Placebo
NCT01004289 phase2completednot on this mapstarted 2007, after this paper: background citation

POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study (POST-AMI)

TypeinterventionalSponsorUniversity of PadovaRan2007 to 2010Enrolled78ConditionsMyocardial Reperfusion InjuryArmsPostconditioning, Primary angioplasty and stenting without additional intervention
3 · Its place in the literature

Who cites it

260 citing papers in PubMed, 30 syntheses or guidelines pooled it, 1,124 citations in OpenAlex.

  1. Guideline
  2. Guideline
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019
    Guideline
  12. Pharmacotherapy for hypertension in adults 60 years or older.The Cochrane database of systematic reviews · 2019
    Pooled it
  13. Pooled it
  14. Pooled it
  15. First-line drugs for hypertension.The Cochrane database of systematic reviews · 2018
    Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. Pooled it

200 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Eugene BraunwaldHarvard Medical School and Brigham and Women's Hospital, Boston, MA 02115, USA.
Michael J Domanski
Sarah E Fowler
Nancy L Geller
Bernard J Gersh
Judith Hsia
Marc A Pfeffer
Madeline M Rice
Yves D Rosenberg
Jean L Rouleau
PEACE Trial Investigators
Brigham and Women's Hospital · US

Funding

PREVENTION OF EVENTS WITH ACE INHIBITORS--CLINICAL TRIAL-268965149N01HC065149 · HC · GEORGE WASHINGTON UNIVERSITY · 1996 to 2003
$3.1M
NHLBI NIH HHS N01 HC065149
6 · The paper itself

Abstract

backgroundAngiotensin-converting-enzyme (ACE) inhibitors are effective in reducing the risk of heart failure, myocardial infarction, and death from cardiovascular causes in patients with left ventricular systolic dysfunction or heart failure. ACE inhibitors have also been shown to reduce atherosclerotic complications in patients who have vascular disease without heart failure.

methodsIn the Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial, we tested the hypothesis that patients with stable coronary artery disease and normal or slightly reduced left ventricular function derive therapeutic benefit from the addition of ACE inhibitors to modern conventional therapy. The trial was a double-blind, placebo-controlled study in which 8290 patients were randomly assigned to receive either trandolapril at a target dose of 4 mg per day (4158 patients) or matching placebo (4132 patients).

resultsThe mean (+/-SD) age of the patients was 64+/-8 years, the mean blood pressure 133+/-17/78+/-10 mm Hg, and the mean left ventricular ejection fraction 58+/-9 percent. The patients received intensive treatment, with 72 percent having previously undergone coronary revascularization and 70 percent receiving lipid-lowering drugs. The incidence of the primary end point--death from cardiovascular causes, myocardial infarction, or coronary revascularization--was 21.9 percent in the trandolapril group, as compared with 22.5 percent in the placebo group (hazard ratio in the trandolapril group, 0.96; 95 percent confidence interval, 0.88 to 1.06; P=0.43) over a median follow-up period of 4.8 years.

conclusionsIn patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors in patients with vascular disease, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization.

Indexed as

AgedAngiotensin-Converting Enzyme InhibitorsBlood PressureCardiovascular DiseasesCoronary DiseaseDouble-Blind MethodDrug Therapy, CombinationFemaleFollow-Up StudiesHumansIndolesMaleMiddle AgedMyocardial InfarctionMyocardial RevascularizationRenin-Angiotensin SystemAngiotensin-Converting Enzyme InhibitorsIndolestrandolapril

Identifiers

PMID15531767
PMCPMC2556374
OpenAlexW2106244081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.